Autoimmune Diseases

Autoimmune diseases pose a major challenge to health systems around the world, impacting the lives of millions. These chronic diseases usually cause the immune system of the body to inflict damage on the body. Additionally, autoimmune diseases cause chronic and acute inflammation and damage to the systems within the body. Protheragen is at the forefront of developing innovative therapies and compounds targeting MyD88 pathways to address the critical unmet needs in autoimmune disease research and development.

Introduction to Autoimmune Diseases

Autoimmune diseases are a distinct and the most difficult chronic diseases of the modern world. The body's immune system, which is in charge of offering defense and protection, instead chooses to battles with the body's healthier cells and tissues. The consequence of this reaction is severe damage to healthy tissues and inflammation of parts of the body. The body and environment play a role in determining the start and development of this disease.

MyD88 in Autoimmune Pathogenesis

In autoimmune diseases, the failure of the immune system to maintain tolerance results in chronic inflammation, activation of specific lymph nodes, and synthesis of autoantibodies. Myeloid Differentiation Primary Response 88 (MyD88) plays a role in the immune system's response and inflammation's MyD88. MyD88 is an adaptor protein that is essential for TLRs and IL-1R family receptors downstream signaling.

In the chronic stage of autoimmune diseases, it is believed that the MyD88-mediated TLR-IL-1R signaling is an essential factor in maintaining inflammation and tissue damage. For example, MyD88 signaling dysregulation will lead to excess production of TNF-α, IL-1β, and IL-6, which fuels inflammation in the arthritis and systemic lupus. MyD88 blocking is believed to provide a good opportunity to control autoimmune overdrive and inflammation damage to tissues.

Targeting MyD88 for the Therapeutic Development in Autoimmune Diseases

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Protheragen offers complete and integrated services for the discovery and development of novel compounds and therapies targeting MyD88 for autoimmune diseases. Protheragen has a dedicated team of scientists with specialized expertise in accelerating the discovery and development processes who offer tailored therapeutic discovery and disease model development services.

MyD88-Targeted Autoimmune Diseases

Protheragen focuses on the research and development of innovative therapies for autoimmune diseases involving MyD88 pathways for triggers and mediators, and is actively supporting preclinical development on these diseases. We appreciate the broad protective role the immune system plays in keeping the body healthy, which profoundly affects the development and manifestation of these disorders. Protheragen offers comprehensive MyD88-centric solutions for the following autoimmune diseases:

Therapeutic Discovery Platform for Autoimmune Diseases

Protheragen's robust therapeutic development services cover the entire scope of drug discovery and preclinical development, with a specific focus on MyD88-related targets:

Disease Models Development for Autoimmune Diseases

To accurately assess the efficacy and safety of MyD88-targeted therapies, Protheragen offers a wide range of advanced disease model development services:

Protheragen specializes in providing one-stop preclinical development services dedicated to advancing MyD88-targeted therapeutics for autoimmune diseases. Our end-to-end solutions streamline the drug development process, from disease model development to in-depth pharmacokinetics and drug safety evaluation. Other focuses include investigator-initiated trials aimed at expediting the primary assessment stage.

If you are interested in our services, please don't hesitate to contact us.

References

• Chen, R., et al. "Pattern Recognition Receptors: Function, Regulation and Therapeutic Potential." Signal Transduct Target Ther 10.1 (2025): 216.
• Yoon, S. B., et al. "A Novel Irak4/Pim1 Inhibitor Ameliorates Rheumatoid Arthritis and Lymphoid Malignancy by Blocking the Tlr/Myd88-Mediated Nf-Kappab Pathway." Acta Pharm Sin B 13.3 (2023): 1093-109.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.